Decoy Therapeutics Reports Worsening Q1 Net Loss of $2.22M; Cash Runway into Late 2026
summarizeSummary
Decoy Therapeutics reported a net loss of $(2.22M) for Q1 2026, which worsened from $(1.71M) in the prior year's quarter, while remaining pre-revenue. This quarterly update provides new financial insight following the amended 10-K filing in April. For a company with a very small market capitalization, a $2.22 million quarterly net loss represents a substantial cash burn relative to its valuation. Critically, the company expects its cash on hand to support operations only into late 2026, signaling a near-term need for additional financing that could be highly dilutive. Traders will be watching for any future financing announcements and updates on the company's cash position and development milestones.
At the time of this announcement, DCOY was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $5.15 to $415.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.